Division of Rheumatology, Department of Medicine, Washington University School of Medicine, St. Louis, MO 63110.
Medical Scientist Training Program, Washington University School of Medicine, St. Louis, MO 63110.
Proc Natl Acad Sci U S A. 2017 Oct 3;114(40):E8440-E8447. doi: 10.1073/pnas.1713064114. Epub 2017 Sep 18.
Natural killer (NK) cells express MHC class I (MHC-I)-specific receptors, such as Ly49A, that inhibit killing of cells expressing self-MHC-I. Self-MHC-I also "licenses" NK cells to become responsive to activating stimuli and regulates the surface level of NK-cell inhibitory receptors. However, the mechanisms of action resulting from these interactions of the Ly49s with their MHC-I ligands, particularly in vivo, have been controversial. Definitive studies could be derived from mice with targeted mutations in inhibitory Ly49s, but there are inherent challenges in specifically altering a single gene within a multigene family. Herein, we generated a knock-in mouse with a targeted mutation in the immunoreceptor tyrosine-based inhibitory motif (ITIM) of Ly49A that abolished the inhibitory function of Ly49A in cytotoxicity assays. This mutant Ly49A caused a licensing defect in NK cells, but the surface expression of Ly49A was unaltered. Moreover, NK cells that expressed this mutant Ly49A exhibited an altered inhibitory receptor repertoire. These results demonstrate that Ly49A ITIM signaling is critical for NK-cell effector inhibition, licensing, and receptor repertoire development.
自然杀伤 (NK) 细胞表达 MHC Ⅰ类 (MHC-I) 特异性受体,如 Ly49A,其抑制杀伤表达自身 MHC-I 的细胞。自身 MHC-I 还“授权”NK 细胞对激活刺激产生反应,并调节 NK 细胞抑制性受体的表面水平。然而,这些 Ly49 与 MHC-I 配体相互作用所产生的作用机制,特别是在体内,一直存在争议。通过对抑制性 Ly49 进行靶向突变的小鼠可以得出明确的研究结果,但在多基因家族中特异性改变单个基因存在固有挑战。在此,我们生成了一种嵌合小鼠,其 Ly49A 的免疫受体酪氨酸基抑制基序 (ITIM) 发生了靶向突变,从而在细胞毒性测定中消除了 Ly49A 的抑制功能。这种突变的 Ly49A 导致 NK 细胞的许可缺陷,但 Ly49A 的表面表达没有改变。此外,表达这种突变 Ly49A 的 NK 细胞表现出改变的抑制性受体谱。这些结果表明,Ly49A ITIM 信号对于 NK 细胞效应器的抑制、许可和受体谱的发展至关重要。